Co-presenter, Sean Shirk, Pharm.D., director of specialty clinical solutions at Prime Therapeutics, discussed this topic during a presentation on legislative impacts on site of service at the AMCP 2025 annual meeting in Houston on Tuesday.
Site-neutral payments have become a significant topic in healthcare legislation, with growing discussions around their potential impact on cost savings and patient care.
While these legislative changes aim to reduce healthcare costs, they also raise concerns about how they could affect patients' access to care and their treatment outcomes.
At the AMCP 2025 annual meeting in Houston—running from March 31 to April 3—these areas were explored amongst professionals in attendance, particularly in the context of Medicare and commercial payers.
Sean Shirk, Pharm.D., director of specialty clinical solutions at Prime Therapeutics, addressed these key points in a session he co-presented, titled “Legislative Impacts on Site of Service: What is the Big Deal?”
Shirk presented the session alongside a Prime associate, Connie Estep, Pharm.D., BCGP, director of specialty clinical solutions.
During the presentation, Shirk addressed the challenges surrounding site-neutral payment policies and their effects on patient care.
He explained that while there has been little progress in this area with the new administration in Congress, the issue remains a high priority.
“I don’t think we’ve heard of it yet, but it’s still very early,” Shirk said. “We haven’t heard any word on whether or not things are going to be moving forward with the new administration or not.”
Shirk stressed the potential cost-saving benefits of site-neutral payments, more specifically in the space of hospital outpatient infusions, which can be much more expensive than alternative settings such as home infusion.
However, he also noted concerns that a focus on cost alone could overlook the importance of patient adherence and convenience.
“Patients are more adherent to their therapy when you lessen those barriers to access and you make it more convenient for them to have a nurse, for example, come to their home and perform the infusion versus them not even being aware that that exists due to site-neutral payment, where they're still going to the hospital outpatient facility, which costs them time, missed hours of work, etc.,” he said.
Shirk also noted that while some states, such as New York, have considered site-neutral payment legislation, no changes have been enacted yet.
Specialty Drugs Dominate Pharmaceutical Frontier in 2025
April 15th 2025In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.
Read More
340B Program Is Driving Up Costs and Needs Urgent Reform | AMCP Annual 2025
April 7th 2025At the 2025 AMCP annual meeting in Houston from March 31 to April 3, John M. O'Brien, Pharm.D., MPH, president and CEO of the National Pharmaceutical Council (NPC), shared concerns and potential reforms in a conversation with Managed Healthcare Executive.
Read More
Exploring the Wide World of GLP-1s | AMCP Annual 2025
April 3rd 2025Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their effects on various other conditions, such as sleep apnea, substance use disorder and Alzheimer’s disease, according to panelists participating in a keynote session of the Academy of Managed Care Pharmacy annual meeting today in Houston.
Read More